Welcome to our dedicated page for Silexion Therapeutics SEC filings (Ticker: SLXNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Silexion Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Silexion Therapeutics's regulatory disclosures and financial reporting.
Silexion Therapeutics Corp reported that CFO and Secretary Hadar Mirit Horenshtein acquired 49,726 Ordinary Shares on account of a fully vested restricted share unit grant. The RSUs were immediately settled into ordinary shares as compensation for service as an officer, approved by the board of directors.
Following this grant, Horenshtein directly owns 50,146 Ordinary Shares of Silexion Therapeutics Corp.
Hadar Ilan reported acquisition or exercise transactions in this Form 4 filing.
Silexion Therapeutics Corp Chairman and CEO Hadar Ilan received a grant of 64,350 fully vested restricted share units that were immediately settled into ordinary shares at a price of $0.0000 per share, as compensation for officer services and approved by the board. Following this award, Ilan directly holds 65,471 ordinary shares. The filing also lists 956 stock options to buy ordinary shares for informational purposes only, with no new option transaction reported.
Abramov Dror Yosef reported acquisition or exercise transactions in this Form 4 filing.
Silexion Therapeutics Corp director Abramov Dror Yosef reported equity awards on February 20, 2026. He received 9,091 ordinary shares through a grant of fully vested restricted share units that were immediately settled into shares for his director services, as approved by the board.
He was also granted 10,685 stock options to buy ordinary shares, with these options vesting in full on the one-year anniversary of the board’s approval date and expiring ten years after that approval. Following these awards, he held 10,180 ordinary shares directly, and a separate line shows 935 stock options as an existing holding included for informational purposes.
Peled Amnon reported acquisition or exercise transactions in this Form 4 filing.
Silexion Therapeutics Corp director Amnon Peled received equity awards from the company. On February 20, 2026, he was granted 7,576 ordinary shares at no cost through fully vested restricted share units issued for his director services.
On the same date, he was also granted stock options for 8,904 ordinary shares, with the options vesting in full one year after the board’s approval date and expiring ten years after that approval. An additional option holding of 780 shares was reported for informational purposes only, with no transactions effected in that line.
Lushi Avner reported acquisition or exercise transactions in this Form 4 filing.
Silexion Therapeutics Corp reported that Guangzhou Sino-Israel Biotech Fund, an entity associated with director Lushi Avner, received equity awards for director services. The fund was granted 9,091 ordinary shares via fully vested RSUs and 10,685 stock options. These options vest in full on the one-year anniversary of board approval and expire ten years after that approval date. An additional 1,872 stock options are reported as existing holdings with no new transaction.
Silexion Therapeutics Corp is asking shareholders at a March 16, 2026 extraordinary general meeting to approve two key changes. The first would increase authorized share capital from 9,000,000 to 59,000,000 ordinary shares, mainly to support financing, business development and compliance with Nasdaq’s $2.5 million shareholders’ equity requirement. The second would amend the 2024 Equity Incentive Plan so the annual “evergreen” refresh can raise the total equity incentive pool up to 10% of issued and outstanding ordinary shares on a fully diluted basis. As of February 23, 2026, Silexion had 3,330,785 ordinary shares outstanding. The board unanimously recommends voting in favor of both proposals.
Silexion Therapeutics Corp received an amended Schedule 13G reporting that Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC together beneficially own 325,000 ordinary shares, or about 9.4% of the company, as of December 31, 2025.
The reported position consists entirely of warrants held by Intracoastal Capital LLC, which are exercisable into 325,000 ordinary shares through two separate warrants of 162,500 shares each. All voting and dispositive power over these shares is shared among the reporting persons, with no sole voting or dispositive authority.
An additional 32,100 shares underlying a third warrant are excluded because that warrant has a 4.99% beneficial ownership blocker, which limits exercises that would push the group’s ownership above that threshold.
Silexion Therapeutics Corp furnished an investor presentation in connection with a non-deal roadshow. The company prepared a corporate presentation dated February 2026 for use in meetings with investors, and attached it as Exhibit 99.1. This material is provided under Regulation FD as a furnished, not filed, communication under securities laws.
Silexion Therapeutics Corp Schedule 13D/A reports that Moringa-related parties disclosed ownership totaling approximately 14.6% of the company's ordinary shares. The filing states Silexion issued 450,000 ordinary shares to Moringa Sponsor, LP on September 15, 2025, in conversion of $1.8 million of an outstanding promissory note, but the Reporting Persons expressly dispute the validity of that issuance and do not concede beneficial ownership of those shares. The cover-page totals combine 6,970 issued ordinary shares, 372 ordinary shares underlying warrants and the 450,000 shares the Reporting Persons contest. The Reporting Persons also reported a pro rata distribution on August 7, 2025 of certain shares and warrants to limited partners.
The reporting persons—Lind Global Fund III LP, Lind Global Partners III LLC and Jeff Easton—filed a Schedule 13G reporting beneficial ownership of 224,050 ordinary shares of Silexion Therapeutics Corp (CUSIP G1281K122), representing 9.9% of the class. The disclosed position consists of 106,250 ordinary shares and warrants (106,250 Series A-1 and 106,250 Series A-2) subject to conversion limits that cap aggregate beneficial ownership at 224,050 shares to prevent ownership above 9.99%. Lind Global Partners III LLC is the general partner of the fund and Jeff Easton is the managing member; each may be deemed to have sole voting and dispositive power over the reported shares. The filers certify the holdings were not acquired to change or influence control of the issuer.